End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13,390 KRW | -2.69% | -1.18% | +16.74% |
01-29 | Zimbabwe launches door-to-door cholera vaccination campaign | RE |
2023 | Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 Trial | CI |
Sales 2024 * | 116B 83.75M 115M | Sales 2025 * | 128B 92.42M 127M | Capitalization | 489B 353M 486M |
---|---|---|---|---|---|
Net income 2024 * | 29B 20.94M 28.83M | Net income 2025 * | 34B 24.55M 33.8M | EV / Sales 2024 * | 4.33 x |
Net Debt 2024 * | 14B 10.11M 13.92M | Net Debt 2025 * | 14B 10.11M 13.92M | EV / Sales 2025 * | 3.93 x |
P/E ratio 2024 * |
16.6
x | P/E ratio 2025 * |
14.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.14% |
1 day | -2.69% | ||
1 week | -1.18% | ||
Current month | +10.48% | ||
1 month | +10.48% | ||
3 months | +23.18% | ||
6 months | +44.60% | ||
Current year | +16.74% |
Managers | Title | Age | Since |
---|---|---|---|
Yeong-Ok Baek
CEO | Chief Executive Officer | 61 | 04-12-31 |
Suk-Keun Choi
DFI | Director of Finance/CFO | 57 | 10-07-31 |
Kyeong-Ho Min
BRD | Director/Board Member | 55 | 10-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Suk-Keun Choi
DFI | Director of Finance/CFO | 57 | 10-07-31 |
Yeong-Ok Baek
CEO | Chief Executive Officer | 61 | 04-12-31 |
Kyeong-Ho Min
BRD | Director/Board Member | 55 | 10-11-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 13,390 | -2.69% | 385,803 |
24-04-29 | 13,760 | -1.08% | 424,525 |
24-04-26 | 13,910 | +0.58% | 859,800 |
24-04-25 | 13,830 | +2.90% | 681,143 |
24-04-24 | 13,440 | -1.18% | 538,128 |
End-of-day quote Korea S.E., April 29, 2024
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+16.74% | 353M | |
-4.24% | 86.85B | |
+2.76% | 40.16B | |
-16.74% | 31.28B | |
+57.86% | 25.27B | |
-14.28% | 15.33B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+6.89% | 8.83B | |
-10.53% | 7.94B |
- Stock Market
- Equities
- A206650 Stock